Inside Sources: Importing Drug Price Controls From Abroad Will Hurt American Consumers

Policymakers should reject efforts to tether U.S. drug prices to an international index. Though consumers may benefit from price reductions in the short-term, such a policy in the long run would shrink patient access to life-saving medicines, slash pharmaceutical R&D, and undermine the IP rights of American companies.

This op-ed is available in Inside Sources.

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin